FiercePharma

Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD

It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. So how much impact has souped-up Eylea had on the ...
FiercePharma

Amid Eylea clash, Roche's Vabysmo keeps climbing despite a slowdown in its momentum

While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea ...
Business Insider

Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema

Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has ...
Fox2Now St. Louis

Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints

EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly ...
abc27

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to ...

Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, ...
Nasdaq

Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies

Roche RHHBY announced positive top-line long-term results from two global late-stage studies on the ophthalmology drug Vabysmo (faricimab). The phase III BALATON and COMINO studies are evaluating the ...